Monopar Therapeutics Files 8-K Current Report
Ticker: MNPR · Form: 8-K · Filed: 2024-02-27T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, regulatory-filing, disclosure
TL;DR
**Monopar Therapeutics filed an 8-K on Feb 27, but the specific event details are missing from this excerpt.**
AI Summary
Monopar Therapeutics Inc. filed an 8-K Current Report on February 27, 2024, disclosing Regulation FD information and Financial Statements and Exhibits. The specific details of these disclosures, including any particular names, dollar amounts, or the nature of the events, are not provided in this filing excerpt.
Why It Matters
This filing indicates Monopar Therapeutics is making a public disclosure, which could contain material information for investors. However, the real-world impact cannot be assessed without the actual content of the Regulation FD disclosure or the financial statements.
Risk Assessment
Risk Level: medium — The filing itself is a standard regulatory disclosure; without the content of the reported events, no specific financial or operational risk can be assessed.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — registrant
- Delaware (company) — state of incorporation
- 001-39070 (dollar_amount) — SEC File Number
- February 27, 2024 (date) — date of earliest event reported
FAQ
What type of SEC filing is this document?
This document is an 8-K Current Report, filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Who is the registrant named in this filing?
The registrant is MONOPAR THERAPEUTICS INC.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is February 27, 2024.
What specific items are mentioned as being disclosed in this 8-K?
The filing indicates 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as item information.
What is the business address of Monopar Therapeutics Inc.?
The business address of Monopar Therapeutics Inc. is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
From the Filing
0001437749-24-005624.txt : 20240227 0001437749-24-005624.hdr.sgml : 20240227 20240227065957 ACCESSION NUMBER: 0001437749-24-005624 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240227 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 24681905 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240226_8k.htm FORM 8-K mnpr20240226_8k.htm false 0001645469 0001645469 2024-02-27 2024-02-27     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 27, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock , $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On February 27, 2024, Monopar Therapeutics Inc. issued a press release announcing the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients.     The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release Dated February 27, 2024 104